DUBLIN–(BUSINESS WIRE)–The “Anaplastic Lymphoma Kinase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Anaplastic lymphoma kinase inhibitors – Pipeline Insight, 2021” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic lymphoma kinase inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Anaplastic lymphoma kinase inhibitors Emerging Drugs Chapters
This segment of the Anaplastic lymphoma kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaplastic lymphoma kinase inhibitors Emerging Drugs
Ensartinib: Betta Pharmaceuticals
Ensartinib hydrochloride is a potent and highly selective next-generation ALK inhibitor with independent intellectual property rights, and it is developed jointly by Betta Pharmaceuticals Co., Ltd. and its subsidiary Xcovey Holding, Inc. (Xcovery). Ensartinib hydrochloride is another product following the EGFR-TKI in Betta’s lung cancer pipeline, and it is expected to be the first innovative targeted drug for lung cancer which is launched globally by a Chinese company. Currently, it is in phase 3 stage of development for the treatment of Non-small cell lung cancer.
TPX 0131: Turning Point Therapeutics
TPX-0131 is a next-generation ALK inhibitor entering IND-enabling studies. It has been designed with a novel compact macrocyclic structure and has shown preclinical potent inhibition of wildtype and numerous ALK mutations, including the clinically observed G1202R solvent-front mutation and the G1202R/L1196M compound mutation. Currently, it is in phase of development stage for the treatment of Non-small cell lung cancer.
Anaplastic lymphoma kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Anaplastic lymphoma kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Anaplastic lymphoma kinase inhibitors
There are approx. 15+ key companies which are developing the Anaplastic lymphoma kinase inhibitors. The companies which have their Anaplastic lymphoma kinase inhibitors drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.
Phases
This report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Anaplastic lymphoma kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Anaplastic lymphoma kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anaplastic lymphoma kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaplastic lymphoma kinase inhibitors drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic lymphoma kinase inhibitors R&D. The therapies under development are focused on novel approaches for Anaplastic lymphoma kinase inhibitors.
Anaplastic lymphoma kinase inhibitors Report Insights
- Anaplastic lymphoma kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Anaplastic lymphoma kinase inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Anaplastic lymphoma kinase inhibitors drugs?
- How many Anaplastic lymphoma kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anaplastic lymphoma kinase inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anaplastic lymphoma kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anaplastic lymphoma kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Betta Pharmaceuticals
- Turning Point Therapeutics
- Nuvalent
- Roche
- LegoChem Biosciences
- Pfizer
- Qilu Pharmaceutical
- Ascentage Pharma
- Suzhou Zelgen Biopharmaceuticals
- Chia Tai Tianqing Pharmaceutical Group
- Beijing Pearl Biotechnology
- Novartis
Key Products
- Ensartinib
- TPX 0131
- NVL 655
- Alectinib
- RF A089
- Lorlatinib
- WX 0593
- APG 2449
- Crizotinib
- Alkotinib
- TQ-B3139
- PLB1003
- Ceritinib
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/f0351p
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900